The application of 13C-methacetin breath test in the assessment of reserved liver function and prognosis of patients with acute on chronic liver failure
刘磊,韩涛,聂彩云,阚志超,李岩,肖时湘,李莹,刘华,阎俊卿
DOI: https://doi.org/10.3760/cma.j.issn.1000-6680.2013.11.008
2013-01-01
Abstract:Objective To investigate the clinical value of 13C-methacetin breath test (13C MBT) in the assessment of reserved liver function and prognosis of patients with acute on chronic liver failure by observing the characteristic of 13C-MBT.Methods Eighty-seven patients with acute on chronic liver failure (divided into early,middle and late stage subgroups),36 patients with chronic hepatitis (mild or moderate type) and 56 patients with cirrhosis (compensative cirrhosis with Child-Pugh score of A) serving as controls were included in this study.All subjects received 13C-MBT,routine liver function test,renal function test and coagulation test after an overnight fast.Meanwhile model for end-stage liver disease (MELD) score was calculated.The three major parameters of 13C-MBT,i.e.maximum excretion rate before 40 min (MVmax40),13CO2 cumulative excretion of 40 min (CUM40) and that of 120 min (CUM120) were recorded,and quantification value was calculated.Two metabolism curves (delta over baseline and metabolisation velosity curve) were drawn.Patients with acute on chronic liver failure were divided into survival group (43 patients) and death group (44 patients) by 3 months follow-up.Quantified value of 13C-MBT,total bilirubin (TBil),prothrombin activity (PTA),international normalized ratio (INR) and MELD were performed by the receiver-operator-characteristic curve analysis (ROC curve analysis).Results The three parameters of 13C-MBT and the quantification value were all significantly statistically different among the three groups.In patients with acute on chronic liver failure,chronic hepatitis,and compensated cirrhosis,the MVmax40 were 0.70 ±0.14,0.34 ± 0.09 and 0.14 ±0.07,respectively (F=38.08,P＜0.01),CUM40 were 0.75 ±0.17,0.34 ± 0.09 and 0.11±0.06,respectively (F=18.23,P＜0.01),CUM120 were 0.74±0.18,0.46±0.13 and 0.21 ± 0.11,respectively (F=21.56,P＜0.01),and the quantification values were 0.73 ± 0.15,0.34±0.13 and 0.21 ± 0.11,respectively (F =17.82,P＜ 0.01).For patients in subgroups with early,middle,and late stages of acute on chronic liver failure,the MVmax40,CUM40,CUM120,and the quantification values,the differences were significant (F=6.34,5.53,11.12,and 10.97,all P＜0.05).The area under curve (AUC) of quantification value of 13C-MBT,TBil,PTA,INR,MELD and Cr were 0.71,0.67,0.80,0.81,0.88,and 0.87,respectively.When the quantification value of 13C-MBT was equal to 0.14,the sensitivity was 63.6％ and specificity was 69.8％ in the assessment of prognosis.Prognostic analysis of 3 month survival with 13C-MBT quantification cut off value of 0.14 showed that the mortality rate was 22.45％ (11/49) when 13C-MBT quantification values were≥0.14,and 86.84 ％ (33/38) when 13C-MBT quantification values were ＜0.14 (x2 =4.89,P＜ 0.05).Conclusions The values of the three parameters and the quantification value of 13C-MBT decrease with the severity of the liver disease and 13C-MBT may be used to evaluate the reserved hepatic function in patients with acute on chronic liver failure.MELD is the best diagnostic method,while 13C-MBT is a better supplementary method to assess the reserved hepatic function and prognosis of patients with acute on chronic liver failure independently.When the quantification value of 13C-MBT is less than 0.14,the prognosis is poor.